More young children are catching walking pneumonia this year, as cases of the respiratory illness continue to surge around the country.

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Student Health reports higher cases of respiratory infections this season, including a few cases of pertussis — also known as ...

The annual meeting of the Infectious Diseases Society of America was held this year from Oct. 16 to 19 in Los Angeles, ...

This infectious respiratory illness is on the rise, especially among children. Here's what parents need to know.

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

(This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...